Seattle, WA based Atossa Genetics Inc. (NasdaqCM: ATOS) is a clinical-stage drug company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions. They believe their innovative therapies and delivery methods can transform breast cancer treatment– with the goals of preventing breast cancer from developing in the first place to increase the odds of surviving for those who do develop this deadly disease.

Approximately one in eight women will be diagnosed with breast cancer during their lifetime. Every two minutes an American woman is diagnosed with breast cancer; 40,000 die each year. Tamoxifen has been widely used for over 30 years for breast cancer. Additional research has shown that it is the metabolites of tamoxifen, of which endoxifen is the most active, that have potential therapeutic value.

Atossa is the only company in the WORLD attempting to conquer breast cancer in the manner that they have stated: “The best way to treat a disease is to prevent it in the first place.” They are developing a topical drug, a lotion applied to each breast, to treat a condition known as high breast density. Third-party studies have shown that high breast density increases the risk of developing breast cancer in some women. Breast density is diagnosed by mammography and approximately 10 million women have high density in the U.S. Tamoxifen has been demonstrated to reduce density and the incidence of breast cancer. However, tamoxifen can have serious side effects because, as a drug taken orally, it is delivered “systemically” meaning it travels throughout the body to other areas the drug is not needed. The goal of their topical endoxifen program is to treat high breast density with a local, topical drug.

Atossa is also developing a new way to deliver pharmaceuticals – through microcatheters (small tubes that can be inserted with anesthetic, through the nipple) so that pharmaceuticals can be targeted to the tissue where breast cancer actually grows.

Their proprietary oral and topical forms of endoxifen are the subject of a comprehensive Phase 1 clinical study in healthy women in Australia. Their patented microcatheter technology is in a Phase 2 clinical study that is also currently enrolling patients.

Here's What The Experts Are Saying

Company News Around The Web

Day Low
Day High
Average Volume
Market Cap
Shares Outstanding
P/E Ratio
Dividend Yield
- -
0.00%% 0.00
Ticker -
Exchange -
Open -
Day Low - High -
Average Volume
Year Low - High -
Market Cap -
Shares Outstanding -
P/E -
Dividend/Yield -
Institutional Ownership -